Effect | Decrease |
Values | No data provided. |
Trial Design | Randomized trial |
Trial Length | 1-6 months |
Number of Subjects | 89 |
Sex | Both Genders |
Age Range | 18-29, 30-44, 45-64, 65+ |
In a randomized, double-blind, placebo-controlled trial, 89 participants with mild to moderate depression were allocated to take 340 mg of SHR-5 Rhodiola Rosea extract, 680 mg, or placebo for 6 weeks.
The primary outcome was depression, and there were statistically significant reductions in both Rhodiola groups for the Beck Depression Inventory and Hamilton Rating Scale for Depression. There were also statistically significant improvements in insomnia, emotional stability, and somatization, though the author didn't provide data.